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Abstract In recent years, Raman spectroscopy has shown
substantive promise in diagnosing bladder cancer, especially
due to its exquisite molecular specificity. The ability to
reduce false detection rates in comparison to existing diag-
nostic tools such as photodynamic diagnosis makes Raman
spectroscopy particularly attractive as a complementary di-
agnostic tool for real-time guidance of transurethral resec-
tion of bladder tumor (TURBT). Nevertheless, the state-of-
the-art high-volume Raman spectroscopic probes have not
reached the expected levels of specificity thereby impeding
their clinical translation. To address this issue, we propose
the use of a confocal Raman probe for bladder cancer
diagnosis that can boost the specificity of the diagnostic
algorithm based on its suppression of the out-of-focus non-
analyte-specific signals emanating from the neighboring
normal tissue. In this article, we engineer and apply such a
probe, having depth of field of approximately 280 μm, for
Raman spectral acquisition from ex vivo normal and can-
cerous TURBT samples. Using this clinical dataset, a diag-
nostic algorithm based on principal component analysis and
logistic regression is developed. We demonstrate that this
approach results in comparable sensitivity but significantly
higher specificity in relation to high-volume Raman spectral
data. The application of only two principal components is
sufficient for the discrimination of the samples underlining
the robustness of the algorithm. Further, no discordance
between replicate spectra is observed emphasizing the re-
producible nature of the current diagnostic assessment. The
high levels of sensitivity and specificity achieved in this
proof-of-concept study opens substantive avenues for appli-
cation of a confocal Raman probe during endoscopic pro-
cedures related to diagnosis and treatment of bladder cancer.
Keywords Confocal Raman spectroscopy . Urinary bladder
cancer . Optical diagnosis . Raman probe . Transurethal
resection of bladder tumor
Introduction
Urinary bladder cancer accounts for 5–10 % of all cancers in
the United States and Europe and is the fourth most com-
mon cancer in men [1]. The majority of diagnosed patients
(75–85 %) suffer from non-muscle invasive disease, which
is characterized by a probability of recurrence in the range
of 31–78 % within 5 years of initial diagnosis [2]. Currently,
flexible cystoscopy and voided urine cytology are employed
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for diagnosis of patients with symptoms suggestive of blad-
der cancer. In particular, if flexible cystoscopy confirms a
bladder tumor or urine cytology shows malignant cells in
the absence of an upper urinary tract urothelial tumor, a rigid
white light cystoscopy (WLC) under general or regional
anesthesia is performed with transurethral resection of blad-
der tumor (TURBT), where applicable.
The ultimate goal in the management of non-muscle
invasive transitional cell carcinoma (TCC) of the bladder
is the prevention of disease recurrence and progression.
Early cancer detection is an essential prerequisite of suc-
cessful therapy. Unfortunately, small papillary bladder
tumors and flat urothelial tumors such as carcinoma in situ
(CIS) can easily be overlooked during conventional WLC.
Moreover, progression to muscle invasive or metastatic
TCC is more likely to occur in those with concomitant
CIS [3]. Additionally, while the application of photodynam-
ic diagnosis (PDD) is known to enhance the sensitivity of
bladder cancer detection from ca. 75 % (for conventional
WLC) to ca. 95 % (for PDD) and increase the recurrence
free survival by 67 % [4, 5], significantly larger false detec-
tion rates (of the order of 40 %) have impeded the path
towards full adoption of this methodology [6–8]. Also, from
an economic standpoint, non-muscle invasive TCC of the
bladder is one of the most expensive cancers to manage on a
per patient basis [9], because of its high prevalence, high
recurrence rate and the need for long-term cystoscopic
surveillance.
In order to meet the substantive unmet clinical need for
an accurate and robust real-time diagnostic tool, several
methods including optical imaging and spectroscopy have
been explored by investigators over the past decade [10, 11].
In particular, Raman spectroscopy has emerged as one of the
promising approaches as it interrogates the molecular com-
position of the tissue in real time without necessitating the
addition of exogenous dyes or labels thereby providing an
objective picture of the pathology with minimal perturbation
to the sample under investigation. By measuring changes in
the wavelength of light scattered from a sample, the bio-
chemical makeup of the tissue may be inferred. In conjunc-
tion with multivariate chemometric methodologies that
analyze the spectral information available over all the spec-
tral channels [12], Raman spectroscopy has been shown to
provide clinically relevant diagnostic information in a wide
variety of disease types ranging from atherosclerosis to
breast and skin cancer [13–17]. Minimally invasive endo-
scopic techniques aimed at detection of cancer cells in the
lining of the urinary bladder using biophotonic technology
such as Raman spectroscopy can interrogate the molecular
composition of the cells and provide an objective and highly
specific picture of the pathology. In this regard, female
patients and patients with a TURBT or/and intravesical
adjuvant treatment within 3 months of cystoscopic
examination [18] are likely to receive maximum benefits
due to the exquisite specificity of Raman-based diagnosis.
This group of patients is at an increased risk of having
benign conditions (including inflammation of bladder mu-
cosa), which appears similar to cancer under the white light
cystoscopic examination. It is expected that a highly specific
technology would provide point measurements using an
optical probe and accurately analyze tissues without remov-
ing it and, therefore, direct biopsies to areas more likely to
contain cancers. In effect, this approach should reduce the
number of unnecessary endoscopic biopsies and prevent
biopsy related morbidity and cost. We envisage Raman
spectroscopy as a complementary diagnostic tool that will
work in combination with the existing fluorescence cystos-
copy techniques to enhance the overall diagnostic value for
bladder cancer determination.
To this end, Stone and co-workers have shown that
Raman microscopy can provide sensitivities and specific-
ities >90 % in an eight-group algorithm for bladder tissue
samples [19]. The next step in the progression was also
taken by the same group when they reported a fiber-optic-
based clinical Raman system that was able to discriminate
between (snap-frozen) benign and malignant bladder sam-
ples with an overall accuracy of 84 % [20]. These founda-
tional works paved the way for in vivo translation of the
Raman-based diagnostic approach. In this regard, one of the
most promising recent investigations was conducted by
Draga and co-workers [21], where they described bladder
cancer diagnosis in vivo using high-volume Raman spectro-
scopic probes. Using multivariate classification models,
they have reported the ability to distinguish cancer from
normal tissue with a sensitivity of 85 % and specificity of
79 %.
However, the underlying rationale for using Raman spec-
troscopy resides in the potentially higher specificity of
Raman-based diagnosis in relation to PDD or fluorescence
cystoscopy. The relatively low specificity of this latest in
vivo study presents a substantive challenge to the clinical
translation of Raman spectroscopy. The goal of this paper is
to make optimal use of the specificity of Raman spectros-
copy to substantially reduce the number of false detection
rates, even at the risk of slightly comprising on the sensitiv-
ity metric. In this context, the large sampling volume of
conventional Raman spectroscopy probes has a deleterious
diagnostic impact due to the confounding (out-of-focus)
signals of the spectral interferents and fluorescence arising
from neighboring normal tissue, as also noted by Draga and
co-workers [21]. In order to overcome this high (and non-
specific) sampling volume-based constraint, we propose and
employ a confocal Raman spectroscopy probe that has a
sampling depth of less than 300 μm. We hypothesize that
the limited sampling depth of our probe provides a superior
platform for measuring the grade and aggressive potential of
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tumors typically observed in bladder cancer cases such as
carcinoma in situ. In this article, we assess the diagnostic
potential of such a system, for the first time, in tumors
removed from patients undergoing TURBT. Importantly,
we show that this system results in comparable sensitivity
to that using high-volume Raman probes but in significantly
higher specificity. It is remarkable that such a high value of
specificity can be obtained using only two principal compo-
nents in the diagnostic algorithm, which further emphasizes
the robustness of the proposed methodology to noise and
potential spurious correlations. The proof-of-concept inves-
tigation outlined in this paper should serve as the foundation
for future work to establish endoscopic application of con-
focal Raman spectroscopy in a larger number of patients.
We anticipate that in larger clinical datasets, one can not
only detect bladder cancer but also demarcate the stage of its
invasion using the proposed approach.
Materials and methods
Raman instrumentation
The Raman spectroscopy system used for the ex vivo tissue
measurements in this study consists of a 785 nm diode laser
(Laser2000, UK) temperature stabilized for Raman excita-
tion, a modified high throughput HoloSpec spectrometer
(Kaiser Inc.) and a front illuminated iDUS CCD camera
(Andor Inc., UK). The light was delivered to a spot of ca.
1 mm2 area (where the power at the sample was approxi-
mately 60 mW) and collected from the tissue using a Raman
probe, whose design is identical to the Motz probe described
in detail elsewhere [22, 23]. Briefly, the collection compo-
nent of our probe consisted of ten tightly packed low-OH
200 μm core optical fibers (Thorlabs Inc.), for Raman signal
collection where the low-OH content of the fiber reduces the
generation of the large fluorescence signal. In addition, an
identical optical fiber of 200 μm core was used for Raman
signal excitation. A bandpass filter (Semrock Inc., USA)
was used at the tip of the excitation fiber and a longpass
filter (Semrock Inc., USA) was used at the tip of collection
fibers. The bandpass filter blocks the background generated
in the excitation fiber and the longpass filter blocks the laser
(and Rayleigh scattered) light entering the collection fibers.
A ball lens (Knight Opticals, UK) was used at the tip of the
excitation fiber to deliver the light to the tissue. Medical
glue (Henkel, Germany) was used for assembly of the
various optical and mechanical components in the probe.
A steel tube (Small Parts Inc., USA) was utilized for the
outermost sheath to add mechanical rigidity to the entire
assembly. In the ensuing discussion, we will refer to this
probe as the high-volume Raman probe to distinguish it
from the confocal variant described below.
As mentioned in the “Introduction”, for a probe to be
sufficiently specific to analyze the region of interest where
cancerous and pre-cancerous cells can be observed, and to
preclude the dilution of the Raman signal of this region, it is
imperative to develop a probe with limited sampling depth.
This issue is addressed by incorporating confocality into the
aforementioned high-volume probe. In particular, light from
the proximal end of the collection fibers is focused on to a
pinhole aperture of diameter 150 μm (Thorlabs Inc.). The
light transmitted through the pinhole is collimated and sub-
sequently focused onto the spectrograph slit. Here, the pin-
hole constitutes the primary confocal aperture (rather than
the optical fibers themselves), which enables the increase or
decrease of the depth of field by switching to a pinhole of
different dimension. Such alteration of depth of field does
not require any change in design and fabrication of the
Raman fiber probe itself. Additionally, the current design
facilitates the acquisition of Raman spectra using both mo-
dalities, namely the high-volume and confocal probe, by
simply removing/adding the pinhole to the system. This, in
turn, permits the direct comparison of the performance of
the confocal probe vis-à-vis that of the high-volume one.
The depth of field of both the high-volume and confocal
Raman probes was determined empirically by measuring the
intensity of the Raman peak (856 cm−1) of a thin film of
dried 4-acetaminophen powder on a quartz substrate as it
was axially translated. The depth of field determined by the
full-width at half-maximum (FWHM) value was 520 and
280 μm, for the high-volume and confocal Raman probes,
respectively. The depth of field estimated for the high-
volume Raman probe is comparable to the sampling depths
of typical Raman probes that report a collection depth in the
range of 500 μm [22–24]. Evidently, these values refer to
the depth of field in this (reflective) substrate whereas the
presence of multiple or diffuse scattering, inherent in bio-
logical samples, is prone to increasing the aforementioned
dimensions.
The Raman data of the normal and diseased bladder
tissue was collected by the confocal and high-volume
Raman probes. Raman spectra were acquired in the wave-
number range of 400 to 1,700 cm−1 for the fingerprint
region from bladder tissue. The acquisition time of each
Raman spectrum is 5 s/frame with five frames per tissue
site. The laser power used at the tissue surface was ca.
30 mW. The spectral resolution of our Raman system was
measured to be 15 cm−1 using the FWHM of the aforemen-
tioned Raman peak of 4-acetaminophen powder.
Acquisition of Raman spectra from bladder tissue
The present study was conducted at the Ninewells Hospital
Medical Research Institute with the approval of the local
ethics committee (Ref. No. 10/S1401/29) and was further
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monitored by the Research and Development Department of
the Tayside Academic Health Science Centre. All patients
signed an informed consent permitting the collection of
Raman spectra on the tissues resected during transurethral
resection of urinary bladder cancer. The ex vivo study
described here provides a relatively well-controlled setting
(in relation to in vivo investigations) for the direct compar-
ison of the effectiveness of the confocal and high-volume
Raman probes. In this study, Raman spectra were acquired
from 28 freshly excised tissue samples from a total of 14
patients. In particular, the two Raman spectra were acquired
from a site in the grossly normal region and another from the
grossly suspicious region of the biopsied tissue, respective-
ly. A photograph of a representative non-muscle invasive
high-grade tumor in a bladder diverticulum is given in
Fig. 1. The Raman probe was placed in gentle contact with
the tissue samples and multiple Raman spectra (5) were
obtained from each tissue site within 5 min of tissue resec-
tion. As a result, 140 ex vivo Raman spectra (for each
probe) were collected from 14 suspected cancer tissue sites
and 14 grossly normal sites. Immediately after the Raman
acquisitions, the biopsy samples were sent to the histopa-
thology department in 10 % formalin solution for examina-
tion by a senior uropathologist. The normal tissue sites as
well as the suspected cancer sites (transitional cell carcino-
ma in situ and squamous cell carcinoma in situ) were con-
firmed by histopathology in all 14 patients. In order to
objectively assess the diagnostic sensitivity and specificity
of Raman spectroscopy for cancer tissue classification, the
histopathological results were used as the gold standard. The
relevant clinical information (class label and spectral data-
set) with donor information removed was submitted to the
MIT Spectroscopy Laboratory for chemometric analysis and
interpretation of the spectroscopic results.
Data analysis
The raw Raman spectra acquired from ex vivo tissue were
composed of the intrinsic Raman signals of the various
biomarkers, intense autofluorescence backgrounds and var-
ious noise components (primarily consisting of shot noise
and detector noise). The signals obtained were vertically
binned and subsequently subjected to cosmic ray removal
[25]. Each Raman spectrum was then selected in the range
of 800 to 1,700 cm−1 to avoid spurious artifacts arising from
the fiber background in the lower wavenumber region.
In this study, to investigate the classification ability of the
proposed method between cancer and normal biopsied sam-
ples from different patients, we first implemented principal
component analysis (PCA) (part of the Statistics Toolbox in
MATLAB R2010b (MathWorks, Natick, MA)) on the entire
140 spectra dataset. PCA is a powerful mathematical tool
for exploratory data analysis, which employs an orthogonal
transformation to convert a set of observations of possibly
correlated variables into a set of values of linearly uncorre-
lated variables called principal components (PC). Impor-
tantly, the transformation is performed to account for the
maximum variability in the dataset using only a few PC,
where each succeeding PC is orthogonal to the previous
ones and explains as much as possible of the remaining
variance. Here, we have used the PCs for visualization of
the important features in the normal and cancerous tissue
samples as well as used the corresponding scores in a
logistic regression algorithm to quantify the classification
accuracy of the proposed approach [26]. A likelihood ratio
test was used to determine the PCs most significant for
diagnosis. Also, a standard leave-one-out cross-validation
protocol [27] was used for the logistic regression analysis.
In this protocol, the data from a particular tissue site is
eliminated, and logistic regression is used to form a decision
line that classifies the remaining tissue sites maximizing
agreement with the histopathology diagnoses. The decision
line is subsequently used to classify the excluded site. This
process is successively applied to each of the [28] sites. The
entire analysis procedure is performed separately for the
high-volume and confocal Raman datasets.
Results and discussion
Distinguishable Raman bands were observed in both normal
and urinary bladder cancer tissue consistent with the fea-
tures observed by Draga and co-workers [21] albeit with
lower signal-to-noise ratio (SNR). The inferior SNR in our
confocal Raman spectra (in comparison to our high-volume
Fig. 1 Photograph showing non-muscle invasive high-grade tumor in
a bladder diverticulum. The normal epithelium of bladder around and
within diverticulum is indicated in the figure. These subtle mucosal
changes can be often be missed by white light cystoscopy
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Raman spectra as well as that noted in the literature [21])
hinders the ready visualization of the important features,
even though the necessary information of the biomarkers
is embedded in this dataset. To elucidate this information,
PCA was implemented on the dataset consisting of 140
confocal Raman spectra. Figure 2 shows the two most
relevant principal components from a diagnostic standpoint,
as determined by the likelihood ratio test. These PCs are the
first (91.6 %) and third (3.73 %) in terms of explaining the
net variance in the dataset—and along with PC 2 (which is
largely characteristic of the signal background) accounts for
99.83 % of the total variance. Specifically, PC1 and PC3
highlight the importance of the spectral features at ca. 878,
1,004, 1,184, 1,308, 1,440 (shoulder), and 1,553 cm−1.
While a perfect one-to-one correspondence between features
observed in principal components and the relevant Raman
peaks of constituents is difficult to establish, these features
can be tentatively assigned to hydroxyproline (878 cm−1),
phenylalanine (1,004 cm−1), DNA (cytosine, guanine and
adenine) (1,184 cm−1), symmetric CH deformation
(1,308 cm−1), CH2 deformation (1,440 cm
−1), and trypto-
phan (1,553 cm−1). It bears mentioning that there may be
alternative interpretations and/or contributions from uniden-
tified constituents to these features, as some of the features
exhibit different FWHM than typically obtained in standard
samples (such as the 1,004 cm−1 peak of phenylalanine).
Here, we also note that PC1 and PC3 share some common
features. Furthermore, we also observe a prominent peak at
ca. 1,390–1,405 cm−1 (in PC1 as well as in PC3), which was
not listed amongst the prominent bands earlier [21]. The
origin of this band is unclear at this present time and needs
further investigation.
The linear projections’ plot of the corresponding scores
for PCs 1 and 3 is shown in Fig. 3. As noted above, scores
for PC2 were not included in this plot because of its inability
to add substantive discriminative ability to the model (this
finding is not wholly unexpected, as other investigators
have reported that the parameters which contribute most to
the fit of spectroscopic data to a model may not be the
parameters with the most diagnostic utility [28]). It is evi-
dent that very good separation is obtained between a large
majority of the normal and cancerous sites. Here, an optimal
separation line was constructed by logistic regression anal-
ysis (in auto-prediction mode) to distinguish the two data
segments, as shown by the black line in Fig. 3. The equation
of the line was determined to be:
0:0015 score1  0:0214 score3 þ 0:9641 ¼ 0 ð1Þ
In order to more objectively quantify the discrimination
ability, leave-one-out cross-validation based logistic
Fig. 2 Plot of principal component (PC) 1 and 3, which provide the
most significant discrimination between the tissue types, namely can-
cerous and normal TURBT samples. These two principal components,
along with PC2, explain 99.83 % of the net variance in the dataset
Fig. 3 Logistic regression-based Raman algorithm distinguishing can-
cerous lesions (red circles) from normal sites (blue circles), as classi-
fied by histopathological examination. The x- and y-axes represent the
scores corresponding to PC 1 and 3, respectively
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regression was subsequently undertaken on the PC scores of
the confocal Raman dataset. The results obtained from this
analysis are enumerated in the confusion matrix of Table 1.
The confusion matrix indicates that we have ten false-
negative data points (arising from two sites) and, remark-
ably, no false-positive points. This translates to sensitivity
(Se) of 85.7 %, specificity (Sp) of 100 %, positive predictive
value of 100 % and negative predictive value of 87.5 % for
the diagnostic algorithm (Table 2). In addition, the overall
accuracy is computed to be 92.9 % and the area under the
curve (AUC) for the corresponding receiver operating charac-
teristic (ROC) curve (Fig. 4) is 0.91 (where a perfect algorithm
has an AUC of 1.00). As leave-one-out cross-validation is
widely accepted as a more robust indicator of the true quality
of the model in relation to auto-prediction (which often results
in over-fitting of the data due to incorporation of noise com-
ponents), the above results provide a high degree of confidence
on the diagnostic value of the proposed method and its poten-
tial for classification of prospective (“unknown”) samples.
Here, we attribute the inaccuracies in classification (i.e.,
the ten false negatives from two cancerous sites) to
spectroscopy-histopathology registration errors [29, 30]. In
other words, the spectroscopic measurements were poten-
tially performed on a grossly normal site of the biopsied
tissue whereas the histopathological results were obtained
for a marginally different position on the tissue where can-
cerous cells could be observed. Also, in general, the exam-
ination region of the two methodologies (namely,
spectroscopy and histopathology) is similar but not identi-
cal—and, arguably, spectroscopy is less prone to sampling
errors inherent in conventional histopathology assessment.
To further elucidate the effectiveness of incorporating
confocality in the Raman probe, we repeated the same data
analysis steps (in conjunction with the given histopathology
labels) for the high-volume Raman spectral dataset. For the
high-volume Raman spectral dataset, the logistic regression
algorithm correctly discriminated 60 out of 70 cancerous
data points, with the inaccuracies arising from the same two
sites as obtained with the confocal Raman probe. However,
ten false-positive points are detected by this algorithm in
contrast to zero such identifications for the confocal Raman
dataset. The resultant sensitivity and specificity values are
both calculated to be 85.7 % for diagnosis of bladder cancer.
For TURBT procedures, the most important diagnostic
parameter is sensitivity, because one would like to identify
every single lesion in patient with the disease for treatment
or further clinical evaluation. Our sensitivity values (ca.
86 %) for both confocal and high-volume Raman probes
are identical and are marginally higher than the sensitivity of
the previous high-volume Raman probe-based study [21].
However, the clear contrast in algorithm performance
appears in the markedly higher specificity values obtained
using our confocal Raman data (100 %). It is worth noting
Table 1 Confusion matrix for leave-one-out cross-validation of logis-
tic regression-based Raman decision algorithm
Histopathology diagnosis
(“Gold Standard”)
Raman spectroscopic diagnosis Cancer Normal Total
Cancer 60 0 60
Normal 10 70 80
Total 70 70 140
Here, the histopathology (“gold standard”) diagnosis is provided along
the columns whereas the Raman classification is given along the rows
Table 2 Comparison of diagnostic performance of leave-one-out
cross-validation Raman algorithm for two sets of assigned labels: the
first row provides the performance metrics for true labels whereas the
second row gives the same for a representative set of randomly
assigned labels




True labels 85.7 100 100 87.5 92.9
Randomized
labels
61.1 27.9 47.3 40.4 45
The performance metrics represented here are: sensitivity (%), speci-
ficity (%), positive predictive value (PPV) (%), negative predictive
value (NPV) (%) and overall accuracy (OA) (%)
Fig. 4 Receiver operating characteristic (ROC) curve illustrating the
ability of confocal Raman spectroscopy to separate cancerous lesions
from normal bladder tissue removed by TURBT. The ROC curve of
two indistinguishable populations, represented by the solid black line,
is included for comparison. For this case, the area under the curve
(AUC) was calculated to be 0.91 (in comparison, the AUC of the solid
black line is 0.5)
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that the discrepancy in performance metrics between our
study and prior investigations may arise from the variations
in properties of the specific samples, quality of the histopa-
thology, and/or mathematical analysis. Hence, the more
meaningful comparison is between our confocal and high-
volume Raman results. The substantive improvement in
specificity signifies immense benefits for female patients
and patients with a TURBT and/or intravesical adjuvant
treatment within 3 months of cystoscopic examination as
the false detection rates of PDD are very high (ca. 40 %).
Clearly, even if false positives do not pose a life-threatening
risk to the patient, the retrieval of additional tissue cores that
were not needed is extremely undesirable and serves only to
drive up the costs (due to additional time spent in TURBT
and the corresponding histopathological examination of un-
necessary tissue cores).
The improvement in the specificity of the diagnostic
algorithm can be attributed to the incorporation of confo-
cality in our probe design. Based on our empirical depth-of-
field value of ca. 280 μm, one can reasonably infer that we
are able to more selectively sample the molecular constitu-
ents at the surface tissue layers in relation to the high-
volume Raman probe used here as well as those used pre-
viously [20, 21]. As stated earlier, this depth-of-field value
is not necessarily an accurate representation of the
corresponding value in a turbid medium (such as biological
tissue) where elastic scattering may considerably reduce the
penetration and collection depth. In particular, we believe
that the confocal probe will help us better diagnose lesion
types where only a few layers of cells (a premalignant
cancer lesion with mucosal thickness of ca. 100 μm) and
carcinoma in situ (which may be composed of only one cell
layer, i.e., 15 μm in thickness). As one can readily observe,
further reduction in confocal range is probably desirable but
would come at the cost of reduction of the intrinsically
weak Raman signal. Stone and co-workers have recently
established the foundation of such development by de-
signing a gradient index lens-based probe with 147 μm
depth of field [31]. Our ex vivo results also compare
favorably with their previous fiber-optic probe-based
investigations where the authors reported an overall
diagnostic accuracy of 84 % in discriminating benign
and malignant bladder lesion by acquiring spectra from
(snap-frozen) in vitro bladder tissue sample [20]. Our
overall accuracy (93 %) is higher in comparison to this
value, although presumably discrimination between the
benign and malignant lesions is more complex in relation
to discrimination between normal and cancer tissue as
performed here.
To verify the robustness of the confocal Raman data to
potential spurious correlations, we implemented an additional
control study. Specifically, the “normal” and “cancer” labels
were assigned in a randomized order without accounting for
their true labels. Using the scores in a leave-one-out cross-
validation logistic regression analysis, we observed that the
new overall accuracy values never reached 60 %, even after
multiple iterations. A representative set of metrics for one of
the iterations is given in Table 2 for comparisonwith the actual
algorithm. This re-iterates the stability of our proposed ap-
proach and its robustness to mis-assigned labels and chance
correlations in the spectral dataset. Further, due to the high
degree of separation obtained using scores for PC 1 and 3, no
diagnostic discordance between spectra acquired from the
same site was observed. Put differently, despite potential
uncertainty in spectroscopic measurements (e.g., shot noise),
the lack of fence-sitters in the current dataset ensured that the
predicted labels from the replicate spectra (i.e., spectra mea-
sured from the same site) were in agreement. This implies that
the precision of Raman measurements in the bladder tissue
obtained using our confocal Raman probe is sufficient to
perform reproducible diagnoses of cancerous lesions.
Conclusion
In this article, we have demonstrated that the specific bio-
chemical information obtained from tissue Raman spectra
shows ample promise for the diagnosis of bladder cancer. In
particular, we have reported the use of a confocal Raman
probe that enables significant enhancement of diagnostic
specificity by suppressing spectral information from deeper
tissue layers beyond the region of interest. We envision that
this finding will be of substantive interest especially given
its implications for endoscopic usage, which is the preferred
route for the diagnosis and treatment of most urological
conditions including urinary bladder cancer.
Furthermore, while the studies performed here provide
the foundation for detection of bladder cancer in TURBT
samples ex vivo, future research work will be necessary to
assess the ability of the technique to provide real-time
guidance for TURBT endoscopic procedures in vivo. The
sensitivity and specificity of the proposed approach may
reduce (slightly) when the Raman algorithm is tested in
large-scale studies in more diverse patient populations. Ad-
ditionally, such studies in the later stages of development
will also require the identification and systematic character-
ization of less common types of lesions not observed in the
initial investigations here. Depending on the number of
classes required and the complexity of the tissue biochem-
ical composition, we will also assess the performance of
other classification algorithms, such as soft independent
modeling class analogy [32] and support vector machines
[33]. Our long-term goal is to evaluate and translate Raman
spectroscopy not only for the real-time detection of cancer-
ous lesions but to be able to discriminate between the grades
and stages of such tumors. We expect that the final outcome
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of the method application to the clinical setups will be a
diagnostic tool that is based on multiple optical/spectroscop-
ic modalities, notably confocal Raman and PDD, where the
hybrid combination may establish a new benchmark in
terms of both sensitivity and specificity.
Our ongoing scientific research will also focus on several
critical aspects that may potentially boost the discrimination
ability with minimal change in hardware. One of the focal
points is the possibility of combining fingerprint Raman
spectra with high-wavenumber information as the latter
region has less (adverse) influence of the tissue autofluor-
escence background. Also, the absence of Raman fiber
signals makes the high-wavenumber approach fairly attrac-
tive for endoscopic applications [34], despite its lower mo-
lecular specificity in comparison to the fingerprint region.
Further, selection of the most informative wavelengths (in-
stead of performing full spectral analysis) [35] as well as
application of pre-processing steps (such as standard normal
variate transformation) that can account for non-analyte-
specific baseline variances is currently under investigation.
Their proper application is likely to generate a more effec-
tive and robust tissue classification algorithm.
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